The approach of Theralink Technologies is based on more than 16 years of research and development. The genomic and transcriptomic information alone provides an incomplete information resource for physicians to make patient-specific treatment decisions.
Private/Public:public
Phone:888-585-4923
Email:[email protected]
Website:https://theralink.com/
Address:Trevor McCartney
15000 West 6th Avenue
Suite 400
Golden, CO 80401, United States of America
2005
Since
1
Country
0
Top Service Category
0
Sub-Service Category
Top Services
United States of America
- (16.Nov.2020) Theralink Technologies Announces Partnership With Perthera to Facilitate and Accelerate Access to Its Unique Phosphoprotein and Drug Target Activation Testing in the U.S
- (29.Sep.2020) Theralink Technologies Appoints Thomas Chilcott as Chief Financial Officer
- (24.Sep.2020) Theralink Technologies Announces Corporate Name Change
- (15.Sep.2020) OncBioMune d/b/a Theralink Technologies Announces Strategic Translational Research Collaboration With BioMed Valley Discoveries
- (09.Sep.2020) Theralink Technologies Achieves Milestone, CLIA Certification for Its Golden, CO Laboratory
- (22.Jul.2020) Theralink Technologies Appoints Michael Fanelli Senior Director, Biopharma Commercial Operations
- (08.Jul.2020) Theralink Technologies Announces Strategic Agreement With VieCure to Improve Outcomes for Breast Cancer Patients Being Treated in Community Oncology Settings
- (17.Jun.2020) OncBioMune D/B/a Theralink Technologies Launches New Corporate Website
- (10.Jun.2020) OncBioMune Appoints Dr. Mick Ruxin as President & CEO and Jeffrey Busch as Chairman of the Board